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Abstract 
Background: The purpose of this study was to address the affects of mood modifying drugs on the 
transcriptome, in a tissue culture model, using qPCR arrays as a cost effective approach to identifying 
regulatory networks and pathways that might coordinate the cell response to a specific drug. 
Methods: We addressed the gene expression profile of 90 plus genes associated with human mood 
disorders using the StellARray™ qPCR gene expression system in the human derived SH-SY5Y 
neuroblastoma cell line. Results: Global Pattern Recognition (GPR) analysis identified a total of 9 
genes (DRD3*, FOS
†
, JUN*, GAD1*
†
, NRG1*, PAFAH1B3*, PER3*, RELN* and RGS4*) to be 
significantly regulated in response to cellular challenge with the mood stabilisers sodium valproate (*) 
and lithium (
†
). Modulation of FOS and JUN highlight the importance of the activator protein 1 (AP-1) 
transcription factor pathway in the cell response. Enrichment analysis of transcriptional networks 
relating to this gene set also identified the transcription factor neuron restrictive silencing factor 
(NRSF) and the oestrogen receptor as an important regulatory mechanism. Limitations: Cell line 
models offer a window of what might happen in vivo but have the benefit of being human derived and 
homogenous with regard to cell type. Conclusions: This data highlights transcription factor pathways, 
acting synergistically or separately, in the modulation of specific neuronal gene networks in response 
to mood stabilising drugs. This model can be utilised in the comparison of the action of multiple drug 
regimes or for initial screening purposes to inform optimal drug design. 
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 Abbreviations: AP-1, activator protein 1; ENCODE, Encyclopaedia of DNA Elements; ERK, 
extracellular-signal-regulated kinase; GPR, Global Pattern Recognition; GxE, Gene x Environment; 
NRSF, neuron restrictive silencing factor; REST, repressor element-1 silencing transcription factor 
1. Introduction 
Mental health is in part dependent upon transcriptional responses to cues which can be 
environmental, chemical, physiological and psychological; this is termed the Gene x Environment 
(GxE) component. These changes not only affect our health in the short term, but can have medium 
to long term impact via epigenetic modulation of gene expression, altering our response to 
environmental challenges. Genetic polymorphism can modulate the GxE response and offer insight 
into the mechanisms underpinning such pathways (Quinn et al., 2013). Earlier genetic studies 
targeted association of one genetic variant to a specific disorder; this had limited success and focused 
predominantly on candidate genes such as those in the monoaminergic pathways. These correlations 
are now being readdressed by analysing multiple variants in such pathways or by stratification of the 
cohorts based on environmental factors. Our recent work on a promoter polymorphism of the 
monoamine oxidase A gene and maternal parameters affecting infant behaviour is an example of the 
latter (Hill et al., 2013). It is difficult to address the signal cascade in response to specific challenges in 
vivo due to the heterogeneity of cells involved in processing the environmental signals mediating a 
cellular response.  However, in vitro cell line models offer an opportunity to address in fine detail the 
signal pathways modulated in response to a specific challenge. In this study we analysed the 
response to distinct drugs in the human neuroblastoma cell line SH-SY5Y targeting a commercially 
available compilation of mood disorder genes to address whether they leave a molecular signature of 
transcriptional change to the challenge. The drugs chosen for comparison included two 
psychostimulant challenges, amphetamine and cocaine, and two mood stabilisers, sodium valproate 
and lithium. All of these drugs have been shown previously to modulate signal pathways in SH-SY5Y 
cells at the transcriptional and/or post-transcriptional level (Asghari et al., 1998; Di Daniel et al., 2005; 
Kantor et al., 2002; Lew, 1992; Pan et al., 2005; Warburton et al., 2014). Our analysis identified 
similarities and differences in the networks modified by the drug challenge which suggested an 
overlap in the pathways of the mood stabilisers. These changes reflect one window for the spectrum 
of changes that could occur in vivo, but nonetheless outline the potential for a concerted cellular 
response to drug exposure.  
  
2. Materials and methods  
 
2.1. Cell culture and drug treatment  
Human derived SH-SY5Y neuroblastoma cells (American Type Culture Collection) were maintained in 
Earle’s modified Eagle’s medium (EMEM) (Sigma) and HAM’s F12 (Sigma) at a ratio of 1:1, 
supplemented with 10% foetal calf serum (FCS) (Sigma), 1% 200mM L-glutamine, 1% 100mM 
sodium pyruvate and 100 U/ml penicillin /100 ug/ml streptomycin at 37°C and 5% CO2. Amphetamine, 
cocaine hydrochloride, lithium chloride and valproic acid sodium salt were purchased from Sigma and 
stock solutions made using sterile filtered dH2O. Drug regimes were 1 hour treatment with either: 
vehicle control (sterile filtered dH2O), 10µM amphetamine (Jones and Kauer, 1999; Shyu et al., 2004), 
10µM cocaine (Warburton et al., 2014), 1mM lithium (Hing et al., 2012; Roberts et al., 2007) or 5mM 
sodium valproate (Pan et al., 2005; Phiel et al., 2001; Zhang et al., 2003). For each drug treatment, 
n=4. Basal (untreated) cells were also included. 
 
2.2. RNA extraction and quantitative polymerase chain reaction (qPCR) analysis  
Total RNA was extracted using Trizol reagent (Invitrogen) and the resulting RNA pellets resuspended 
in RNase-free water. 500ng RNA was reverse transcribed into cDNA using the GoScript
TM
 RT system 
(Promega). qPCR analysis was performed on an iQ5 real-time PCR system (Bio-Rad) using 1µl of 
cDNA per reaction and GoTaq
® 
qPCR Master Mix (Promega) with the addition of Fluorescene 
Calibration Dye (Bio-Rad) at a final concentration of 10nM. Changes in gene expression were 
analysed on the Lonza Web site (http://array.lonza.com/gpr), using the Global Pattern Recognition™ 
(GPR) analysis software designed by Bar Harbor Biotechnology 
(https://www.bhbio.com/BHB/dw/home.html). This algorithm internally normalised the real-time qPCR 
data set of each gene with respect to all genes within the experiment and generated a list of genes 
that are ranked on the basis of the difference between the test and control expression levels and the 
consistency of the data between the biological replicates. This proprietary software calculated both 
the fold-change data and the respective p-values. The results are displayed as change with respect to 
the genes that showed minimal changes, which were defined on Ct values obtained using the Global 
Pattern Recognition analysis software (Akilesh et al., 2003). 
 
A list of genes on the mood array is given in Table 1. 
 
2.3. Bioinformatic analysis 
Gene expression data generated from GPR analysis was uploaded into the online biological pathway 
analysis software MetaCore
TM
, version 6.15 build 62452. Functional enrichment of the experimental 
dataset was performed using: 1) the Pathway Map analysis tool to identify significantly associated 
pathways based on p-value and GPR Fold-change and 2) Build Network for Your Experimental Data 
feature using the Transcription Factor Targets Modelling algorithm with default settings under Analyse 
Networks (Transcription Factors) to generate sub-networks based on the presence of transcription 
factors and/or receptor targets within the original input file. Such genes/proteins uploaded from 
experimental datasets and from which pathways were built upon were termed ‘seed nodes’. 
 
In silico analysis of NRSF binding sites over the significantly altered genes across the different 
treatment conditions from the qPCR array data were identified using Transcription Factor ChIP-seq 
from ENCODE (Encyclopaedia of DNA Elements), version 4, available on the UCSC Genome 
Browser (http://genome.ucsc.edu/index.html). Upstream and downstream flank sequences (10 Kb) 
were included and the position of NRSF binding sites calculated. For genes with multiple transcripts, 
the locus for the largest isoform was used. The full list of NRSF binding sites are detailed in Table 3.    
 
  
3. Results 
 
3.1. Gene expression profiling of human SH-SY5Y cells in response to mood-modifying drugs using 
Global Pattern Recognition analysis 
To investigate the effects of mood modifying drugs on the expression of a panel of genes associated 
with mood disorders (Human Mood Disorder 96 StellARray™), SH-SY5Y neuroblastoma cells after 
treatment for 1 hour under one of the specified conditions were analysed using the proprietary Global 
Pattern Recognition (GPR) algorithm which compares the change in expression of a gene normalised 
to the expression of every other gene in the array (Akilesh et al., 2003). This software calculates both 
the fold-change data and the respective p-values with respect to genes that showed minimal changes. 
We and others have recently demonstrated that drugs used in the treatment of mood  disorders can 
differentially affect the expression stability of traditionally used housekeeping genes, impacting upon 
their usefulness as normalising factors (D'Souza et al., 2013; Powell et al., 2013; Sugden et al., 
2010). Unfortunately, these large changes in gene expression may mask small but biologically 
important changes in gene expression, such as master regulator genes (e.g., transcription factors).  
The data in Table 2 therefore represents a more appropriate display of the genes most changed 
within the experiment by comparing all genes against themselves. As the array contains validated 
mood genes we addressed the top 10 genes which significantly changed in response to each drug to 
define pathways and networks within the larger gene list.   
 
Following treatment with the mood stabiliser sodium valproate, 8 genes were significantly (p<0.05) up- 
or down-regulated compared to the vehicle control; 2 up-regulated (JUN and PAFAH1B3) and 6 
down-regulated (DRD3, GAD1, NRG1, PER3, RELN and RGS4). When compared to the results 
obtained after treatment with another common mood stabiliser, lithium, similarities in the gene 
expression profile with respect to the top 10 altered genes was observed; namely down-regulation of 
GAD1, NRG1, PER3, RELN and RGS4, but, only GAD1 reached statistical significance at this time 
point for lithium treatment. In addition, FOS was significantly down-regulated in response to lithium. 
Treatment with the two psychomotor stimulants cocaine and amphetamine demonstrated no 
statistically significant changes in gene expression following 1 hour treatment. Furthermore the genes 
with the lowest p-values were distinct between the psychostimulants apart from MOBP (Table 2) 
demonstrating that these drugs might be preferentially targeting distinct pathways for their action. 
However due to the low p-values obtained under these experimental conditions we did not pursue 
their analysis further. 
 
3.2. Network analysis of genes significantly modulated in response to mood stabilisers 
To further explore potential gene networks important in the response to drug challenge, we analysed 
only the genes whose expression was most affected by lithium and sodium valproate using the 
Analyse Networks (Transcription Factors) algorithm from MetaCore
TM
. This generates sub-networks 
through relative enrichment of the uploaded dataset based on the presence of transcription factors 
and/or receptor targets within the original input file. The gene set used was composed of GAD1, 
NRG1, PER3, RELN, RGS4, PAFAH1B3, DRD3, FOS and JUN, the first five of which were observed 
for both lithium and sodium valproate and the remaining were those significantly modified in response 
to either exposure. 
 
A network containing NRSF, ErbB2 and ErbB3 as seed nodes was the highest ranked using this 
approach, and was defined as genes/proteins uploaded from experimental datasets or genes/proteins 
directly linked to uploaded gene lists from which networks are built (Figure 1). It included 7 of our 9 
input genes (DRD3, FOS, GAD1, JUN, NRG1, PAFAH1B3 and RELN) and had a p-value of 5.24 x 10
-
29
 based on hypergeometric distribution which calculated the probability of a particular pathway map 
arising by chance given the number of genes across all gene pathways, within a particular pathway or 
sub-network and within the present experimental dataset. The transcription factors identified as being 
important regulators of this network were c-Fos and c-Jun (collectively AP-1), c-Myc, ESR1, NRSF, 
PR, RAR-alpha and SP3. 
 
As our gene expression data showed that 7/9 of the significantly modulated genes were down-
regulated (Table 2) and NRSF which predominantly functions as a transcriptional repressor was 
identified as an important regulator of our gene set, we addressed predicted NRSF binding sites using 
ENCODE data from the Transcription Factor ChIP-seq track (2011; Rosenbloom et al., 2013) on the 
UCSC Genome Browser. This identified NRSF binding at the promoter regions (within 5 Kb of the 
transcriptional start site) of DRD3 (transcript variant a, e and g), FOS, GAD1, JUN, NRG1 (transcript 
variant HRG-gamma1/2/3, HRG-beta1/d-, 2- and 3b, ndf43/b/c,HRG-alpha and SMDF), PAFAH1B3 
and RGS4 (transcript variant 2/3) which, with the  exception of JUN and PAFAH1B3, were all down-
regulated in response to 1 hour treatment with sodium valproate (or lithium with respect to FOS).   
 
To determine how these regulatory pathways were most relevant for mood disorders, we filtered our 
dataset using the MetaCore
TM 
‘Filter by Disease’ feature which traces all of the known associated 
interactions for a particular disease process. This assigned 46.15% of our network, not unexpectedly 
to disease processes relating to mood (Figure 2A). Furthermore, it identified NRSF and ERK1/2 
signalling along the oestrogen receptor pathway as important regulators of processes relevant to 
mood disorders involving this subset of genes. In addition to disorders of the CNS, filtering of our 
dataset by disease showed there to be significant associations (96.15%) with breast, skin and 
gastrointestinal neoplasia; GAD1 being the only gene not to be involved in these cancer-related 
pathologies (Figure 2B). To further assess which signalling pathways may be operating in response to 
challenge with these mood stabilisers, we also filtered our experimental network for Drug Responses 
under the Gene Ontology (GO) Processes filter. This identified the fibroblast growth factor, ERBB and 
neurotrophin TRK receptor signalling pathways as important cellular responses, with the dopamine 
D3 receptor, EGFR, ErbB2, ErbB3 and c-Src highlighted as therapeutic targets (Figure 2C). 
  
4. Discussion 
 
Understanding the mechanism of action for a drug to alter the cell phenotype, in addition to the initial 
cellular targets recognised by the drug, is important for both clinical application and pharmaceutical 
development. Transcriptome profiling allows for global scale interrogation of potential regulatory 
mechanisms involved in modulating cellular responses to a particular drug through the use of pathway 
analysis tools. The aim of this study was to address the effects of mood modifying drugs on the 
expression profile of a commercially available panel of genes associated with mood disorders by 
network analysis to compare and contrast their mode of action.  
 
We used two mood stabilisers (lithium and sodium valproate) and two mood stimulants (cocaine and 
amphetamine). Only the mood stabilisers reached statistical significance and interestingly they shared 
5 genes in their top 9 most modified genes, Table 2; we therefore focused on this set of genes for 
further analysis. Valproate significantly modified 8 genes, lithium only two, GAD1 and FOS, with 
GAD1 being significantly down-regulated for both drugs. GAD1 encodes one of several forms of 
glutamic acid decarboxylase which is a key enzyme for the synthesis of the inhibitory neurotransmitter 
GABA. GAD1 is implicated from both genetic and functional analysis as a modulator of mood 
(Domschke et al., 2013; Hettema et al., 2006; Karolewicz et al., 2010; Lundorf et al., 2005; Thompson 
et al., 2009; Weber et al., 2012). FOS and JUN proteins constitute the AP-1 transcription factor 
complex which was a target for modulation. These factors represent a family of proteins that 
heterodimerise to regulate the AP-1 DNA site (Quinn, 1991; Quinn et al., 1989a; Quinn et al., 1989b; 
Takimoto et al., 1989). Lithium and sodium valproate have both been demonstrated to modulate the 
AP-1 complex (Chen et al., 2008; Ozaki and Chuang, 2002). The genes shared in common by the 
mood stabilisers sodium valproate and lithium were GAD1, NRG1, PER3, RELN and RGS4. The 
remainder, DRD3, JUN and PAFAH1B3 were specific for sodium valproate. Although some of these 
genes were modified with cocaine and amphetamine, the statistical significance was low, certainly 
lower than all the genes in the 9 most differentially expressed genes in Table 2. We have previously 
used cocaine and amphetamine in SH-SY5Y and found that we can observe significant changes in 
genes involved in mental health. For example, recently in the approximate same passage number of 
cells as used in this experiment, we have demonstrated that cocaine altered the expression of the 
schizophrenia candidate gene MIR137 (Warburton et al., 2014). However under the current 
experimental conditions this gene set targeting mood disorders is not responding as robustly to 
cocaine and amphetamine as lithium and sodium valproate. We therefore attempted to determine 
whether the significant mood stabiliser gene set defined a specific pathway or network of genes to 
explain their concerted response to drug exposure. 
 
Pathway analysis using both the Analyse Networks (Transcription Factors) and Filter by Disease 
algorithms available on the online pathway analysis software MetaCore
TM
 identified the transcription 
factor NRSF, also termed REST (repressor element-1 silencing transcription factor), to be strongly 
associated with the pathways supporting these networks of genes. NRSF has a direct association 
with DRD3, GAD1 and RELN genes based on the network analysis, Figure 1. Bioinformatic analysis 
of predicted NRSF binding sites using ENCODE (Encyclopaedia of DNA Elements) data from the 
Transcription Factor ChIP-seq track (2011; Rosenbloom et al., 2013) on the UCSC Genome Browser, 
identified NRSF binding at the promoter regions (within 5 Kb of the transcriptional start site) of the 
FOS, NRG1 and RGS4 genes, Table 3. This ENCODE analysis also demonstrated NRSF binding 
sites in similar genomic locations on DRD3, GAD1, JUN, PAFAH1B3 and RELN. Aberrant signalling 
of NRSF and its target genes has been shown to be involved in the pathophysiology of several CNS 
disorders including schizophrenia (Loe-Mie et al., 2010), major depressive disorder (Otsuki et al., 
2010) and alcoholism and depression (Ukai et al., 2009), with genetic variants influencing age-related 
cognitive function (Miyajima et al., 2008). More recently it has been highlighted as a major player in 
Alzheimer’s disease (Lu et al., 2014). NRSF has the properties to modulate epigenetic factors in its 
target genes due to its association with a plethora of co-activators, such as members of the SWI/SNF 
family, which can modify histones by post-translational modifications (Loe-Mie et al., 2010). These 
epigenetic modifications could result in medium to long term changes in gene expression that underlie 
drug exposure in addition to the immediate modulation of the transcriptome. Our data suggest that 
lithium and sodium valproate, with different initial cellular targets, may modulate related signalling 
pathways leading to overlapping cellular responses mediated in part by the NRSF pathway. It should 
be noted that we performed this experiment at 1 hour post exposure to capture an early response of 
the cell to the drug. As in any stimulus induction modification of gene expression many of these 
changes will be transient, especially in the short term for transcription factors such as AP-1 and 
NRSF. This is in keeping with the transient response of AP-1 and NRSF in stimulus inducible gene 
expression models we have previously observed at 1 hour post exposure (Gillies et al., 2009; Howard 
et al., 2008; Quinn, 1991; Spencer et al., 2006). A more extensive timescale would perhaps have 
demonstrated a different or related set of genes, nevertheless, our strategy allowed the observation of 
the differential gene set acting as a signature for the mood stabilisers and allows for future 
optimisation. 
 
Filtering our dataset by disease also identified ERK1/2 signalling along with the oestrogen receptor 
pathway as a potentially important regulatory network for this gene set (Figure 2). Oestrogen receptor 
signalling has been well documented in the modulation of behaviours relating to aggression (Nomura 
et al., 2002), anxiety and depression (Furuta et al., 2013). The action of sex hormones may in part 
explain why in conditions such as panic disorder these phenotypes are more prevalent among 
females. Our data would be consistent with GAD1 SNP variation being tentatively associated for the 
higher susceptibility of females to panic disorder (Weber et al., 2012) via modulation by oestrogen.  
This oestrogen pathway could overlap with other transcription factor pathways identified in our 
analysis, for example synergistic action of the oestrogen and AP-1 pathways on gene expression 
(Fujimoto and Kitamura, 2004). The extended networks identified in this study (AP-1, oestrogen and 
NRSF) may also work synergistically, for example NRSF activity is important for E2 stimulation of the 
cell cycle (Bronson et al., 2010) and oestrogen receptor B is enriched at NRSF binding sites (Le et al., 
2013). Such interactions between these three pathways can be further modified by the glucocorticoid 
receptor, so linking these pathways to a major driver of mood (Abramovitz et al., 2008; Karmakar et 
al., 2013). Glucocorticoid sensitivity is strongly associated with several mood related disorders 
(Spijker and van Rossum, 2012) and anti-glucocorticoid drugs have been used in the treatment of 
such conditions (Gallagher et al., 2008; Wolkowitz and Reus, 1999; Wolkowitz et al., 1999). Mood 
disorder susceptibility has also been linked to glucocorticoid signalling through its modulation of the 
stress response along the hypothalamic-pituitary–adrenal (HPA) axis (Lupien et al., 2009; Spijker and 
van Rossum, 2012).   
 
Our data points to a cost effective and rapid assessment of expression changes in selected genes 
using GPR analysis, which can help delineate the pathways targeted by drugs to modify mood. In 
particular, we have identified dopamine and glutamine pathways as being important; perhaps not 
unexpectedly as the gene set is enriched for known genes involved in mood disorders. Alteration in 
the regulation of these pathways would be expected to modulate mood and is reflected in the range of 
drugs currently used in targeting these pathways. However the modulation of the AP-1 pathway and 
the involvement of factors such as NRSF and ERK1/2 highlight a more general modulation of 
neurotransmitter pathways in response to mood modifying drugs. Our model can therefore be used to 
determine mechanisms associated with off target and long term affects of particular drugs and can be 
extrapolated to predict in vivo responses, utilised in the comparison of multiple drug regimes or used 
as an initial screening process to inform optimal drug design. 
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Figure 1. Network Analysis of genes significantly modulated in response to mood stabilisers. Genes 
shown to be significantly up or down regulated in human SH-SY5Y cells in response to 1 hour 
treatment with the mood stabilisers sodium valproate and lithium were uploaded into MetaCore
TM
 for 
Network Analysis. The gene list was analysed under the Build Network feature using the Transcription 
Factor Targets Modelling algorithm. Seed nodes from which the network was built upon are 
encompassed by a large circle; blue circles represent genes from the experimental data, green circles 
represent molecules from which the pathway is expanded from and red circles represent molecules 
on which the pathway terminates. Genes uploaded from the experimental data are also marked with a 
smaller circle in their top right hand corner; red circles represent genes that were significantly up-
regulated, whereas blue circles represent genes significantly down-regulated. Connecting arrows 
indicate interactions; green arrows represent activation, red arrows represent inhibition and blue 
arrows are unspecified. Overlaid cyan lines represent canonical pathways. Gene names/symbols 
within the network from top to bottom, left to right: Neuregulin 1, Dopamine D3 receptor, RELN, 
ErbB3, ErbB2, EGFR, Shc, GRB2, MEK1/2, c-Raf-1, GAD1 PAFAH gamma, SOS, c-Src, H-Ras, 
ERK1/2, NRSF, SP3, c-Myc, ESR1 (nuclear), c-Fos, c-Jun/c-Fos, JunD/c-Fos, RARalpha, PR 
(nuclear) c-Jun, and AP-1. 
  
Figure 2. Network analysis filters for disease and gene ontology processes. The network generated in 
relation to genes significantly regulated in response to SH-SY5Y cell treatment with sodium valproate 
and lithium (Figure 1) was filtered to show the relevant disease pathways (A and B) and gene 
ontology processes (C). A-B, Disease processes relevant to mood disorders (A), represents 46.15% 
of the gene network; and breast, skin and gastrointestinal neoplasms (B), represents 96.15% of the 
gene network. C, Gene ontology processes relevant to drug response. Seed nodes from which the 
network was built upon are encompassed by a large blue circle. Genes uploaded from the 
experimental data are also marked with a smaller circle in their top right hand corner; red circles 
represent genes that were significantly up-regulated, whereas blue circles represent genes 
significantly down-regulated. Connecting blue arrows indicate direct interactions, yellow arrows 
indicate interactions that are in the base but do not form part of the network and overlaid cyan lines 
represent canonical pathways. Gene names/symbols within network A, from top to bottom, left to 
right: Neuregulin 1, Dopamine D3 receptor, Reelin, ERK1/2, MEK1/2, NRSF, ESR1 (nuclear), c-Fos, 
c-Jun/c-Fos, JunD/c-Fos, PR (nuclear) and AP-1; B, from top to bottom, left to right: Neuregulin 1, 
Dopamine D3 receptor, Reelin, ErbB3, ErbB2, EGFR, SOS, Shc,GRB2, c-Raf-1,  PAFAH gamma, H-
Ras, c-Src, ERK1/2, MEK1/2,NRSF, SP3, c-Myc, ESR1 (nuclear), c-Fos, c-Jun/c-Fos, JunD/c-Fos, 
RARalpha, PR (nuclear), c-Jun and AP-1; and C, from top to bottom, left to right: Dopamine D3 
receptor,  Reelin, ErbB3, ErbB2,  EGFR, GAD1, c-Src, NRSF, c-Myc, c-Fos, c-Jun/c-Fos, JunD/c-Fos, 
c-Jun and AP-1. 
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Table 1. Gene name and description for the Human Mood Disorder 96-well qPCR StellARray™ 
Gene Name Entrez Gene Description 
ACE 1636 Angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 
ADCYAP1 116 Adenylate cyclase activating polypeptide 1 (pituitary) 
ADRBK2 157 Adrenergic, beta, receptor kinase 2 
ARNTL 406 Aryl hydrocarbon receptor nuclear translocator-like 
ATP2A2 488 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 
BCR 613 Breakpoint cluster region 
BDNF 627 Brain-derived neurotrophic factor 
CASP8 841 Caspase 8, apoptosis-related cysteine peptidase 
CCND2 894 Cyclin D2 
CHRNA7 1139 Cholinergic receptor, nicotinic, alpha 7 
CIT 11113 Citron rho-interacting serine/threonine kinase 
CLOCK 9575 Clock circadian regulator 
COMT 1312 Catechol-O-methyltransferase 
CREB1 1385 CAMP responsive element binding protein 1 
CRH 1392 Corticotropin releasing hormone 
CRHBP 1393 Corticotropin releasing hormone binding protein 
DAO 1610 D-amino-acid oxidase 
DISC1 27185 Disrupted in schizophrenia 1 
DLX1 1745 Distal-less homeobox 1 
DRD1 1812 Dopamine receptor D1 
DRD3 1814 Dopamine receptor D3 
DRD4 1815 Dopamine receptor D4 
DTNBP1 84062 Dystrobrevin binding protein 1 
ERBB3 2065 V-erb-b2 erythroblastic leukemia viral oncogene homolog 3 
FAT1 2195 FAT atypical cadherin 1 
FKBP5 2289 FK506 binding protein 5 
FOS 2353 FBJ murine osteosarcoma viral oncogene homolog 
GABRA5 2558 Gamma-aminobutyric acid (GABA) A receptor, alpha 5 
GAD1 2571 Glutamate decarboxylase 1 (brain, 67kDa) 
GCH1 2643 GTP cyclohydrolase 1 
GPR50 9248 G protein-coupled receptor 50 
GRIK3 2899 Glutamate receptor, ionotropic, kainate 3 
GRIK4 2900 Glutamate receptor, ionotropic, kainate 4 
GRIN2B 2904 Glutamate receptor, ionotropic, N-methyl D-aspartate 2B 
GRM3 2913 Glutamate receptor, metabotropic 3 
GRM4 2914 Glutamate receptor, metabotropic 4 
GSK3B 2932 Glycogen synthase kinase 3 beta 
Hs18s - Human 18S ribosomal RNA 
HS Genomic - Human genomic DNA control 
HSP90B1 7184 Heat shock protein 90kDa beta (Grp94), member 1 
HSPA5 3309 Heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) 
HTR1B 3351 5-hydroxytryptamine (serotonin) receptor 1B 
HTR2A 3356 5-hydroxytryptamine (serotonin) receptor 2A 
IL1RN 3557 Interleukin 1 receptor antagonist 
IMPA1 3612 Inositol(myo)-1(or 4)-monophosphatase 1 
IMPA2 3613 Inositol(myo)-1(or 4)-monophosphatase 2 
INPP1 3628 Inositol polyphosphate-1-phosphatase 
ISYNA1 51477 Myo-inositol 1-phosphate synthase A1 
JUN 3725 Jun oncogene 
KCNN3 3782 Potassium intermediate/small conductance calcium-activated channel, 
subfamily N, member 3 
MAG 27307 Malignancy-associated gene 
Table(s)
  
MAL 4118 Mal, T-cell differentiation protein 
MAOA 4128 Monoamine oxidase A 
MLC1 23209 Megalencephalic leukoencephalopathy with subcortical cysts 1 
MOBP 4336 Myelin-associated oligodendrocyte basic protein 
MOG 4340 Myelin oligodendrocyte glycoprotein 
MTHFR 4524 5,10-methylenetetrahydrofolate reductase (NADPH) 
NAPG 8774 N-ethylmaleimide-sensitive factor attachment protein, gamma 
NCAM1 4684 Neural cell adhesion molecule 1 
ND4 4538 Mitochondrially encoded NADH dehydrogenase 4 
NDUFV1 4723 NADH dehydrogenase (ubiquinone) flavoprotein 1, 51kDa 
NDUFV2 4729 NADH dehydrogenase (ubiquinone) flavoprotein 2, 24kDa 
NOS1AP 9722 Nitric oxide synthase 1 (neuronal) adaptor protein 
NR1D1 9572 Nuclear receptor subfamily 1, group D, member 1 
NR3C1 2908 Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) 
NRG1 3084 Neuregulin 1 
NTRK2 4915 Neurotrophic tyrosine kinase, receptor, type 2 
OLIG2 10215 Oligodendrocyte lineage transcription factor 2 
P2RX7 5027 Purinergic receptor P2X, ligand-gated ion channel, 7 
PAFAH1B1 5048 Platelet-activating factor acetylhydrolase, isoform Ib, alpha subunit 45kDa 
PAFAH1B3 5050 Platelet-activating factor acetylhydrolase, isoform Ib, gamma subunit 29kDa 
PCNT 5116 Pericentrin 
PDLIM5 10611 PDZ and LIM domain 5 
PER3 8863 Period circadian clock 3 
PIP4K2A 5305 Phosphatidylinositol-5-phosphate 4-kinase, type II, alpha 
PLA2G1B 5319 Phospholipase A2, group IB (pancreas) 
PLA2G4A 5321 Phospholipase A2, group IVA (cytosolic, calcium-dependent) 
PLCG1 5335 Phospholipase C, gamma 1 
PLP1 5354 Proteolipid protein 1 
POLG 5428 Polymerase (DNA directed), gamma 
PTGS2 5743 Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) 
RELN 5649 Reelin 
RFX4 5992 Regulatory factor X, 4 (influences HLA class II expression) 
RGS4 5999 Regulator of G-protein signaling 4 
SLC12A6 9990 Solute carrier family 12 (potassium/chloride transporters), member 6 
SLC6A2 6530 Solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 
SLC6A3 6531 Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 
SLC6A4 6532 Solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 
SULT1A1 6817 Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 
SYNGR1 9145 Synaptogyrin 1 
TAAR6 319100 Trace amine associated receptor 6 
TF 7018 Transferrin 
TIMELESS 8914 Timeless circadian clock 
TPH1 7166 Tryptophan hydroxylase 1 (tryptophan 5-monooxygenase) 
TPH2 121278 Tryptophan hydroxylase 2 
XBP1 7494 X-box binding protein 1 
Table 2. Gene expression profiling of SH-SY5Y cells following exposure to drugs affecting mood. 
Lithium Sodium Valproate 
Gene  Description p  Fold 
change  
Gene  Description p Fold 
change 
FOS  FBJ murine 
osteosarcoma viral 
oncogene homolog 
0.012 -2.57  DRD3  Dopamine receptor D3 0.001  -7.98  
GAD1  Glutamate 
decarboxylase 1 
0.023 -3.48  RGS4  Regulator of G-protein 
signaling 4 
0.007  -2.08  
RGS4  Regulator of G-protein 
signaling 4 
0.063 -1.51  JUN  Jun oncogene 0.008  2.49  
PER3  Period circadian clock 3 0.067 -1.38  RELN  Reelin 0.012  -1.78  
NRG1  Neuregulin 1 0.068 -1.43  PER3  Period circadian clock 3 0.026  -1.48  
NR1D1  Nuclear receptor 
subfamily 1, group D, 
member 1 
0.069 -1.48  PAFAH1B3  Platelet-activating factor 
acetylhydrolase, isoform 
Ib, gamma subunit 29kDa 
0.034  1.61  
RELN  Reelin 0.078 -1.94  GAD1  Glutamate    
decarboxylase 1 
0.035  -7.45  
ACE  Angiotensin I converting 
enzyme (peptidyl-
dipeptidase A) 1 
0.099 1.31  NRG1  Neuregulin 1 0.044  -1.34  
Hs18s  Human 18S ribosomal 
RNA 
0.105 1.64  MTHFR  Methylenetetrahydrofolate 
reductase (NADPH) 
0.083  1.53  
BDNF   Brain-derived 
neurotrophic factor 
 0.106 -1.39  RFX4  Regulatory factor X, 4 
(influences HLA class II 
expression) 
0.092  -1.49  
Cocaine Amphetamine 
Gene  Description p  Fold 
change  
Gene  Description p Fold 
change 
SULT1A1  Sulfotransferase family, 
cytosolic, 1A, phenol-
preferring, member 1 
0.088  1.68  MOBP  Myelin-associated 
oligodendrocyte basic 
protein 
0.080  2.08  
DRD3  Dopamine receptor D3 0.110  -2.08  XBP1  X-box binding protein 1 0.093  1.34  
FOS  FBJ murine 
osteosarcoma viral 
oncogene homolog 
0.142  -1.45  NR1D1  Nuclear receptor subfamily 
1, group D, member 1 
0.109  -1.35  
MOBP  Myelin-associated 
oligodendrocyte basic 
protein 
0.161  1.85  MAG  Malignancy-associated  
gene 
0.138  2.81  
SLC6A2  Solute carrier family 6 
(neurotransmitter 
transporter, noradrenalin), 
member 2 
0.176  -1.28  PAFAH1B3  Platelet-activating factor 
acetylhydrolase, isoform Ib, 
gamma subunit 29kDa 
0.141  1.33  
GRIK3  Glutamate receptor, 
ionotropic, kainate 3 
0.194  -1.67  FKBP5  FK506 binding protein 5 0.159  -1.34  
TIMELESS  Timeless circadian clock 0.200  -1.20  RELN  Reelin 0.198  -1.30  
NCAM1  Neural cell adhesion 
molecule 1 
0.206 -1.20  BCR  Breakpoint cluster region 0.207  1.22  
ND4  Mitochondrially encoded 
NADH dehydrogenase 4 
0.232  1.15  MLC1  Megalencephalic 
leukoencephalopathy with 
subcortical cysts 1 
0.208  2.52  
NR1D1  Nuclear receptor 
subfamily 1, group D, 
member 1 
0.233  -1.28  GABRA5  Gamma-aminobutyric acid 
(GABA) A receptor, alpha 5 
0.213  -1.78  
Table(s)
Top 10 changes in gene expression levels between treated (10 µM amphetamine, 10 µM cocaine, 1 mM lithium and 5 mM sodium valproate) and untreated 
conditions measured using qPCR arrays (Human Mood Disorder 96 StellARrayTM) and Global Pattern Recognition (GPR) statistical analysis. Fold change 
values are represented as treated conditions normalised to the drug vehicle. Bold font indicates significant changes in gene expression, p<0.05.  
 
Table 3. Predicted NRSF regulation of genes affecting mood. 
Gene Locus Strand NRSF site Size (Bp) Position 
ACE chr17:61554422-61575741 + chr17:61553914-61554174 260 -508 
ACE chr17:61554422-61575741 + chr17:61554504-61554774 270 82 
ACE chr17:61554422-61575741 + chr17:61556270-61556594 324 1848 
ACE chr17:61554422-61575741 + chr17:61557174-61557444 270 2752 
ACE chr17:61554422-61575741 + chr17:61558309-61558579 270 3887 
ADRBK2 chr22:25960861-26125258 + chr22:25961290-25961560 270 429 
ADRBK2 chr22:25960861-26125258 + chr22:26052841-26053085 244 91980 
ADRBK2 chr22:25960861-26125258 + chr22:26097050-26097320 270 136189 
ARNTL chr11:13277734-13387266 + chr11:13283216-13283586 370 5482 
ARNTL chr11:13277734-13387266 + chr11:13298458-13299341 883 20724 
ARNTL chr11:13277734-13387266 + chr11:13310624-13311040 416 32890 
ARNTL chr11:13277734-13387266 + chr11:13312905-13313275 370 35171 
ARNTL chr11:13277734-13387266 + chr11:13351630-13351900 270 73896 
ARNTL chr11:13277734-13387266 + chr11:13361071-13361575 504 83337 
ARNTL chr11:13277734-13387266 + chr11:13364729-13364973 244 86995 
ARNTL chr11:13277734-13387266 + chr11:13365612-13366116 504 87878 
BCR chr22:23522552-23660224 + chr22:23525622-23525892 270 3070 
BCR chr22:23522552-23660224 + chr22:23546679-23546949 270 24127 
BCR chr22:23522552-23660224 + chr22:23562075-23562399 324 39523 
BCR chr22:23522552-23660224 + chr22:23566052-23566322 270 43500 
BCR chr22:23522552-23660224 + chr22:23591914-23592184 270 69362 
BCR chr22:23522552-23660224 + chr22:23624008-23624332 324 101456 
BCR chr22:23522552-23660224 + chr22:23647903-23648174 271 125351 
BCR chr22:23522552-23660224 + chr22:23651156-23651400 244 128604 
BDNF chr11:27676442-27743605 - chr11:27667673-27667943 270 -8499 
BDNF chr11:27676442-27743605 - chr11:27671454-27671716 262 -4726 
BDNF chr11:27676442-27743605 - chr11:27680076-27680346 270 63259 
BDNF chr11:27676442-27743605 - chr11:27721240-27721484 244 22121 
BDNF chr11:27676442-27743605 - chr11:27723005-27723329 324 20276 
BDNF chr11:27676442-27743605 - chr11:27739843-27740167 324 3438 
BDNF chr11:27676442-27743605 - chr11:27740692-27741122 430 2483 
BDNF chr11:27676442-27743605 - chr11:27741795-27742502 707 1103 
BDNF chr11:27676442-27743605 - chr11:27742701-27743071 370 534 
BDNF chr11:27676442-27743605 - chr11:27743607-27744258 651 +2 
BDNF chr11:27676442-27743605 - chr11:27744566-27744890 324 +961 
CASP8 chr2:202098166-202152434 + chr2:202096900-202097280 380 -1266 
CASP8 chr2:202098166-202152434 + chr2:202098061-202098441 380 -105 
CASP8 chr2:202098166-202152434 + chr2:202122713-202123093 380 24547 
CRH chr8:67088612-67090846 - chr8:67089099-67090281 1182 565 
CRH chr8:67088612-67090846 - chr8:67090287-67090659 372 187 
CRH chr8:67088612-67090846 - chr8:67090956-67091280 324 +110 
CRH chr8:67088612-67090846 - chr8:67091915-67092285 370 +1069 
CRH chr8:67088612-67090846 - chr8:67098519-67098889 370 +7673 
DISC1 chr1:231762561-232177019 + chr1:231795960-231796330 370 33399 
DISC1 chr1:231762561-232177019 + chr1:231814930-231815200 270 52369 
DISC1 chr1:231762561-232177019 + chr1:231925791-231926295 504 163230 
DISC1 chr1:231762561-232177019 + chr1:231963016-231963520 504 200455 
DISC1 chr1:231762561-232177019 + chr1:231964053-231964309 256 201492 
DISC1 chr1:231762561-232177019 + chr1:232067746-232067990 244 305185 
DISC1 chr1:231762561-232177019 + chr1:232148522-232148892 370 385961 
DRD3 chr3:113847557-113918254 - chr3:113871366-113871690 324 46564 
DRD3 chr3:113847557-113918254 - chr3:113874262-113874642 380 43612 
DRD3 chr3:113847557-113918254 - chr3:113897607-113898013 406 20241 
DRD3 chr3:113847557-113918254 - chr3:113898443-113898813 370 19441 
DRD4 chr11:637305-640705 + chr11:640330-640654 324 3025 
DTNBP1 chr6:15523032-15663289 - chr6:15552018-15552288 270 111001 
DTNBP1 chr6:15523032-15663289 - chr6:15621994-15622224 230 41065 
Table(s)
DTNBP1 chr6:15523032-15663289 - chr6:15662506-15662830 324 459 
FKBP5 chr6:35541362-35696397 - chr6:35656504-35656848 344 39549 
FKBP5 chr6:35541362-35696397 - chr6:35687515-35687759 244 8638 
FKBP5 chr6:35541362-35696397 - chr6:35695292-35695562 270 835 
FKBP5 chr6:35541362-35696397 - chr6:35695873-35696103 230 294 
FKBP5 chr6:35541362-35696397 - chr6:35699743-35700105 362 -3346 
FOS chr14:75745481-75748937 + chr14:75743830-75744074 244 -1651 
FOS chr14:75745481-75748937 + chr14:75745296-75745800 504 -185 
GABRA5 chr15:27111866-27194357 + chr15:27110041-27110545 504 -1825 
GABRA5 chr15:27111866-27194357 + chr15:27111625-27112129 504 -241 
GAD1 chr2:171673200-171717659 + chr2:171670663-171671101 438 -2537 
GAD1 chr2:171673200-171717659 + chr2:171671290-171671546 256 -1910 
GAD1 chr2:171673200-171717659 + chr2:171672190-171672567 377 -1010 
GAD1 chr2:171673200-171717659 + chr2:171679546-171679776 230 6346 
GAD1 chr2:171673200-171717659 + chr2:171701873-171702253 380 28673 
GRIK3 chr1:37261128-37499844 - chr1:37269486-37269856 370 229988 
GRIK3 chr1:37261128-37499844 - chr1:37301874-37302144 270 197700 
GRIK3 chr1:37261128-37499844 - chr1:37329834-37330078 244 169766 
GRIK3 chr1:37261128-37499844 - chr1:37331752-37332256 504 167588 
GRIK3 chr1:37261128-37499844 - chr1:37332540-37332784 244 167060 
GRIK3 chr1:37261128-37499844 - chr1:37388506-37388750 244 111094 
GRIK3 chr1:37261128-37499844 - chr1:37389788-37390253 465 109591 
GRIK3 chr1:37261128-37499844 - chr1:37411488-37411732 244 88112 
GRIK3 chr1:37261128-37499844 - chr1:37431706-37432281 575 67563 
GRIK3 chr1:37261128-37499844 - chr1:37486267-37486654 387 13190 
GRIK3 chr1:37261128-37499844 - chr1:37494616-37494860 244 4984 
GRIK3 chr1:37261128-37499844 - chr1:37504779-37505043 264 -4935 
GRM3 chr7:86273230-86494192 + chr7:86290343-86290599 256 17113 
GRM3 chr7:86273230-86494192 + chr7:86322086-86322456 370 48856 
GRM3 chr7:86273230-86494192 + chr7:86476174-86476554 380 202944 
GRM3 chr7:86273230-86494192 + chr7:86497476-86497720 244 +3284 
JUN chr1:59246463-59249785 - chr1:59249472-59249885 413 -100 
MAG chr19:35782989-35820133 + chr19:35796870-35797100 230 13881 
MAG chr19:35782989-35820133 + chr19:35809956-35810280 324 26967 
MAOA chrX:43,515,409-43,606,068 + - - - 
MLC1 chr22:50,497,820-50,523,781 - - - - 
MOBP chr3:39543557-39567857 + chr3:39540121-39540386 265 -3436 
MOBP chr3:39543557-39567857 + chr3:39558349-39558719 370 14792 
MOBP chr3:39543557-39567857 + chr3:39574318-39574698 380 +6461 
MTHFR chr1:11845787-11866160 - chr1:11845214-11845454 240 +573 
MTHFR chr1:11845787-11866160 - chr1:11850982-11851306 324 14854 
MTHFR chr1:11845787-11866160 - chr1:11856563-11856793 230 9367 
MTHFR chr1:11845787-11866160 - chr1:11857775-11857960 185 8200 
MTHFR chr1:11845787-11866160 - chr1:11858618-11858699 81 7461 
MTHFR chr1:11845787-11866160 - chr1:11863764-11864034 270 2126 
MTHFR chr1:11845787-11866160 - chr1:11865502-11865882 380 278 
MTHFR chr1:11845787-11866160 - chr1:11866038-11866425 387 -265 
NAPG chr18:10525873-10552766 + chr18:10525815-10526242 427 -58 
NCAM1 chr11:112831969-113092626 + chr11:112831909-112832179 270 -60 
NCAM1 chr11:112831969-113092626 + chr11:112977293-112977549 256 145324 
NCAM1 chr11:112831969-113092626 + chr11:113008930-113009200 270 176961 
NCAM1 chr11:112831969-113092626 + chr11:113011853-113012123 270 179884 
NCAM1 chr11:112831969-113092626 + chr11:113023160-113023664 504 191191 
NCAM1 chr11:112831969-113092626 + chr11:113074175-113074445 270 242206 
NR1D1 chr17:38249037-38256973 - chr17:38244467-38244847 380 +4570 
NR1D1 chr17:38249037-38256973 - chr17:38254215-38254595 380 2378 
NR1D1 chr17:38249037-38256973 - chr17:38255228-38255666 438 1307 
NR1D1 chr17:38249037-38256973 - chr17:38256685-38257094 409 -121 
NR1D1 chr17:38249037-38256973 - chr17:38257324-38257828 504 -351 
NR1D1 chr17:38249037-38256973 - chr17:38264445-38264769 324 -7472 
NR3C1 chr5:142657496-142783254 - chr5:142784785-142785394 609 -2140 
NRG1 chr8:31496911-32622558 + chr8:31499444-31499814 370 2533 
NRG1 chr8:31496911-32622558 + chr8:31612484-31612740 256 115573 
NRG1 chr8:31496911-32622558 + chr8:31629195-31629565 370 132284 
NRG1 chr8:31496911-32622558 + chr8:31652781-31653242 461 155870 
NRG1 chr8:31496911-32622558 + chr8:31691004-31691508 504 194093 
NRG1 chr8:31496911-32622558 + chr8:31817830-31818086 256 320919 
NRG1 chr8:31496911-32622558 + chr8:31896212-31896582 370 399301 
NRG1 chr8:31496911-32622558 + chr8:32084240-32084744 504 587329 
NRG1 chr8:31496911-32622558 + chr8:32122327-32122831 504 625416 
NRG1 chr8:31496911-32622558 + chr8:32189091-32189595 504 692180 
NRG1 chr8:31496911-32622558 + chr8:32191794-32192298 504 694883 
NRG1 chr8:31496911-32622558 + chr8:32200953-32201685 732 704042 
NRG1 chr8:31496911-32622558 + chr8:32245491-32245735 244 748580 
NRG1 chr8:31496911-32622558 + chr8:32276508-32276752 244 779597 
NRG1 chr8:31496911-32622558 + chr8:32284202-32284706 504 787291 
NRG1 chr8:31496911-32622558 + chr8:32392615-32392985 370 895704 
NRG1 chr8:31496911-32622558 + chr8:32405958-32406282 324 909047 
NRG1 chr8:31496911-32622558 + chr8:32406492-32406892 400 909581 
NRG1 chr8:31496911-32622558 + chr8:32411341-32411845 504 914430 
NRG1 chr8:31496911-32622558 + chr8:32487206-32487506 300 990295 
NRG1 chr8:31496911-32622558 + chr8:32488853-32489109 256 991942 
NRG1 chr8:31496911-32622558 + chr8:32503654-32504024 370 1006743 
NRG1 chr8:31496911-32622558 + chr8:32546371-32546746 375 1049460 
NRG1 chr8:31496911-32622558 + chr8:32572641-32573145 504 1075730 
NRG1 chr8:31496911-32622558 + chr8:32581201-32581705 504 1084290 
NRG1 chr8:31496911-32622558 + chr8:32582687-32583047 360 1085776 
PAFAH1B3 chr19:42801185-42806952 - chr19:42806435-42806939 504 -13 
PER3 chr1:7844714-7905237 + ~14 Kb upstream of 5’UTR  - - 
PDLIM5 chr4:95373038-95509370 + chr4:95372903-95373283 380 -135 
PDLIM5 chr4:95373038-95509370 + chr4:95406777-95407007 230 33739 
PDLIM5 chr4:95373038-95509370 + chr4:95418920-95419164 244 45882 
PDLIM5 chr4:95373038-95509370 + chr4:95455973-95456203 230 82935 
PDLIM5 chr4:95373038-95509370 + chr4:95456267-95456511 244 83229 
PDLIM5 chr4:95373038-95509370 + chr4:95471601-95471831 230 98563 
PDLIM5 chr4:95373038-95509370 + chr4:95499407-95499663 256 126369 
RELN chr7:103112231-103629963 - chr7:103127865-103128245 380 501718 
RELN chr7:103112231-103629963 - chr7:103276613-103276992 379 352971 
RELN chr7:103112231-103629963 - chr7:103297949-103298179 230 331784 
RELN chr7:103112231-103629963 - chr7:103301028-103301258 230 328705 
RELN chr7:103112231-103629963 - chr7:103354935-103355205 270 274758 
RELN chr7:103112231-103629963 - chr7:103438111-103438481 370 191482 
RELN chr7:103112231-103629963 - chr7:103451010-103451107 97 178856 
RELN chr7:103112231-103629963 - chr7:103484281-103484449 168 145514 
RELN chr7:103112231-103629963 - chr7:103491745-103492249 504 137714 
RELN chr7:103112231-103629963 - chr7:103559848-103560078 230 69885 
RELN chr7:103112231-103629963 - chr7:103580845-103581215 370 48748 
RELN chr7:103112231-103629963 - chr7:103636658-103636861 203 -6898 
RFX4 chr12:106976685-107156582 + chr12:106975282-106975646 364 -1403 
RFX4 chr12:106976685-107156582 + chr12:106975776-106976119 343 -909 
RFX4 chr12:106976685-107156582 + chr12:107147300-107147544 244 170615 
RGS4 chr1:163038396-163046592 + chr1:163039054-163039341 287 658 
SLC12A6 chr15:34522197-34630265 - chr15:34516950-34517512 562 +5247 
SLC12A6 chr15:34522197-34630265 - chr15:34610582-34611086 504 19179 
SLC12A6 chr15:34522197-34630265 - chr15:34630069-34630393 324 -128 
SLC12A6 chr15:34522197-34630265 - chr15:34634991-34635543 552 -4726 
SLC6A2 chr16:55689542-55737700 + chr16:55686047-55686317 270 -3495 
SLC6A2 chr16:55689542-55737700 + chr16:55689638-55689908 270 96 
SLC6A2 chr16:55689542-55737700 + chr16:55690575-55690845 270 1033 
SLC6A2 chr16:55689542-55737700 + chr16:55693927-55694197 270 4385 
SLC6A2 chr16:55689542-55737700 + chr16:55695818-55696088 270 6276 
SLC6A2 chr16:55689542-55737700 + chr16:55696686-55696956 270 7144 
SLC6A2 chr16:55689542-55737700 + chr16:55744402-55744761 359 +7061 
SLC6A2 chr16:55689542-55737700 + chr16:55746277-55746521 244 +8821 
SLC6A4 chr17:28,523,378-28,562,954 - - - - 
SULT1A1 chr16:28616908-28634907 - chr16:28621167-28621407 240 13500 
TF chr3:133419211-133497850 + chr3:133461483-133461863 380 42272 
TF chr3:133419211-133497850 + chr3:133465027-133465407 380 45816 
TF chr3:133419211-133497850 + chr3:133472690-133472920 230 53479 
TIMELESS chr12:56810157-56843200 - chr12:56811537-56811907 370 31293 
TIMELESS chr12:56810157-56843200 - chr12:56842752-56843263 511 -63 
TPH2 chr12:72332626-72426221 + chr12:72332400-72332889 489 -226 
TPH2 chr12:72332626-72426221 + chr12:72374868-72375372 504 42242 
TPH2 chr12:72332626-72426221 + chr12:72410895-72411165 270 78269 
XBP1 chr22:29190548-29196560 - chr22:29196394-29196960 566 -400 
XBP1 chr22:29190548-29196560 - chr22:29198252-29198482 230 -1922 
NRSF binding sites over top 10 affected genes across all drug treatments from Transcription Factor ChIP-seq from ENCODE version 4. Bold font indicates 
genes significantly affected by drug challenge. Negative and positive values under Position represent the location of the NRSF site upstream of the gene 
transcriptional start site and downstream of the 3’UTR, respectively. Values not assigned +/- represent binding sites within the gene sequence. For genes 
with multiple transcripts, binding site positions are with respect to the largest isoform.    
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